Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer

Randall E. Millikan, Sijin Wen, Lance C. Pagliaro, Melissa A. Brown, Brenda Moomey, Kim Anh Do, Christopher J. Logothetis

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Purpose: We conducted a phase III trial in patients with previously untreated metastatic prostate cancer to test the hypothesis that three 8-week cycles of ketoconazole and doxorubicin alternating with vinblastine and estramustine, given in addition to standard androgen deprivation, would delay the appearance of castrate-resistant disease. Patients and Methods: Eligible patients had metastatic prostate cancer threatening enough to justify sustained androgen ablation and were fit enough for chemotherapy. The primary end point was time to castrate-resistant progression as shown by increasing prostate-specific antigen, new radiographic lesions, worsening cancer-related symptoms, or receipt of any other systemic therapy. Results: Three hundred six patients were registered; 286 are reported. Median time to progression was 24 months (95% CI, 18 to 39 months) in the standard therapy arm, and 35 months (95% CI, 26 to 44 months) in the chemohormonal group (P = .39). At median follow-up of 6.4 years, overall survival was 5.4 years (95% CI, 4.7 to 7.8 years) in the standard therapy arm versus 6.1 years (95% CI, 5.1 to 10.1 years; P = .41). Prostate-specific antigen kinetics at the time of androgen ablation and the nadir after hormone treatment were strongly correlated with survival. Chemotherapy significantly increased the burden of therapy, with 51% of patients experiencing an adverse event of grade 3 or worse, especially thromboembolic events. Conclusion: There is no role for ketoconazole and doxorubicin alternating with vinblastine and estramustine before emergence of a castrate-resistant phenotype.

Original languageEnglish (US)
Pages (from-to)5936-5942
Number of pages7
JournalJournal of Clinical Oncology
Volume26
Issue number36
DOIs
StatePublished - Dec 20 2008
Externally publishedYes

Fingerprint

Androgens
Prostatic Neoplasms
Drug Therapy
Estramustine
Ketoconazole
Vinblastine
Prostate-Specific Antigen
Doxorubicin
Therapeutics
Survival
Hormones
Phenotype
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Millikan, R. E., Wen, S., Pagliaro, L. C., Brown, M. A., Moomey, B., Do, K. A., & Logothetis, C. J. (2008). Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. Journal of Clinical Oncology, 26(36), 5936-5942. https://doi.org/10.1200/JCO.2007.15.9830

Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. / Millikan, Randall E.; Wen, Sijin; Pagliaro, Lance C.; Brown, Melissa A.; Moomey, Brenda; Do, Kim Anh; Logothetis, Christopher J.

In: Journal of Clinical Oncology, Vol. 26, No. 36, 20.12.2008, p. 5936-5942.

Research output: Contribution to journalArticle

Millikan, RE, Wen, S, Pagliaro, LC, Brown, MA, Moomey, B, Do, KA & Logothetis, CJ 2008, 'Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer', Journal of Clinical Oncology, vol. 26, no. 36, pp. 5936-5942. https://doi.org/10.1200/JCO.2007.15.9830
Millikan, Randall E. ; Wen, Sijin ; Pagliaro, Lance C. ; Brown, Melissa A. ; Moomey, Brenda ; Do, Kim Anh ; Logothetis, Christopher J. / Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 36. pp. 5936-5942.
@article{47013c91eece404f87f72d6868be80af,
title = "Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer",
abstract = "Purpose: We conducted a phase III trial in patients with previously untreated metastatic prostate cancer to test the hypothesis that three 8-week cycles of ketoconazole and doxorubicin alternating with vinblastine and estramustine, given in addition to standard androgen deprivation, would delay the appearance of castrate-resistant disease. Patients and Methods: Eligible patients had metastatic prostate cancer threatening enough to justify sustained androgen ablation and were fit enough for chemotherapy. The primary end point was time to castrate-resistant progression as shown by increasing prostate-specific antigen, new radiographic lesions, worsening cancer-related symptoms, or receipt of any other systemic therapy. Results: Three hundred six patients were registered; 286 are reported. Median time to progression was 24 months (95{\%} CI, 18 to 39 months) in the standard therapy arm, and 35 months (95{\%} CI, 26 to 44 months) in the chemohormonal group (P = .39). At median follow-up of 6.4 years, overall survival was 5.4 years (95{\%} CI, 4.7 to 7.8 years) in the standard therapy arm versus 6.1 years (95{\%} CI, 5.1 to 10.1 years; P = .41). Prostate-specific antigen kinetics at the time of androgen ablation and the nadir after hormone treatment were strongly correlated with survival. Chemotherapy significantly increased the burden of therapy, with 51{\%} of patients experiencing an adverse event of grade 3 or worse, especially thromboembolic events. Conclusion: There is no role for ketoconazole and doxorubicin alternating with vinblastine and estramustine before emergence of a castrate-resistant phenotype.",
author = "Millikan, {Randall E.} and Sijin Wen and Pagliaro, {Lance C.} and Brown, {Melissa A.} and Brenda Moomey and Do, {Kim Anh} and Logothetis, {Christopher J.}",
year = "2008",
month = "12",
day = "20",
doi = "10.1200/JCO.2007.15.9830",
language = "English (US)",
volume = "26",
pages = "5936--5942",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "36",

}

TY - JOUR

T1 - Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer

AU - Millikan, Randall E.

AU - Wen, Sijin

AU - Pagliaro, Lance C.

AU - Brown, Melissa A.

AU - Moomey, Brenda

AU - Do, Kim Anh

AU - Logothetis, Christopher J.

PY - 2008/12/20

Y1 - 2008/12/20

N2 - Purpose: We conducted a phase III trial in patients with previously untreated metastatic prostate cancer to test the hypothesis that three 8-week cycles of ketoconazole and doxorubicin alternating with vinblastine and estramustine, given in addition to standard androgen deprivation, would delay the appearance of castrate-resistant disease. Patients and Methods: Eligible patients had metastatic prostate cancer threatening enough to justify sustained androgen ablation and were fit enough for chemotherapy. The primary end point was time to castrate-resistant progression as shown by increasing prostate-specific antigen, new radiographic lesions, worsening cancer-related symptoms, or receipt of any other systemic therapy. Results: Three hundred six patients were registered; 286 are reported. Median time to progression was 24 months (95% CI, 18 to 39 months) in the standard therapy arm, and 35 months (95% CI, 26 to 44 months) in the chemohormonal group (P = .39). At median follow-up of 6.4 years, overall survival was 5.4 years (95% CI, 4.7 to 7.8 years) in the standard therapy arm versus 6.1 years (95% CI, 5.1 to 10.1 years; P = .41). Prostate-specific antigen kinetics at the time of androgen ablation and the nadir after hormone treatment were strongly correlated with survival. Chemotherapy significantly increased the burden of therapy, with 51% of patients experiencing an adverse event of grade 3 or worse, especially thromboembolic events. Conclusion: There is no role for ketoconazole and doxorubicin alternating with vinblastine and estramustine before emergence of a castrate-resistant phenotype.

AB - Purpose: We conducted a phase III trial in patients with previously untreated metastatic prostate cancer to test the hypothesis that three 8-week cycles of ketoconazole and doxorubicin alternating with vinblastine and estramustine, given in addition to standard androgen deprivation, would delay the appearance of castrate-resistant disease. Patients and Methods: Eligible patients had metastatic prostate cancer threatening enough to justify sustained androgen ablation and were fit enough for chemotherapy. The primary end point was time to castrate-resistant progression as shown by increasing prostate-specific antigen, new radiographic lesions, worsening cancer-related symptoms, or receipt of any other systemic therapy. Results: Three hundred six patients were registered; 286 are reported. Median time to progression was 24 months (95% CI, 18 to 39 months) in the standard therapy arm, and 35 months (95% CI, 26 to 44 months) in the chemohormonal group (P = .39). At median follow-up of 6.4 years, overall survival was 5.4 years (95% CI, 4.7 to 7.8 years) in the standard therapy arm versus 6.1 years (95% CI, 5.1 to 10.1 years; P = .41). Prostate-specific antigen kinetics at the time of androgen ablation and the nadir after hormone treatment were strongly correlated with survival. Chemotherapy significantly increased the burden of therapy, with 51% of patients experiencing an adverse event of grade 3 or worse, especially thromboembolic events. Conclusion: There is no role for ketoconazole and doxorubicin alternating with vinblastine and estramustine before emergence of a castrate-resistant phenotype.

UR - http://www.scopus.com/inward/record.url?scp=58049221262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58049221262&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.15.9830

DO - 10.1200/JCO.2007.15.9830

M3 - Article

C2 - 19029421

AN - SCOPUS:58049221262

VL - 26

SP - 5936

EP - 5942

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 36

ER -